Skip to content

Promptus

1 viewer · 30d

Total raised

$100K

+$100K this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $100K
ROUNDS
1
INVESTORS
1
FOUNDED
2025
HQ
Denver, CO
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Promptus is a Denver, Colorado healthcare technology venture that develops validated medical IP into commercial-ready devices in house. Its first program is Safyr, a wearable cardiovascular sensing platform built on proprietary Vascular Impedance Mapping (VIM) technology, initially in a smart ring form factor. VIM uses a circular multi-sensor electrode array to measure changes in electrical impedance as blood flows through tissue, instead of the optical (PPG) sensing used by most wearables. The company reports a USPTO notice of allowance for the VIM patent in February 2026, an engineering partnership with Swiss research organization CSEM, pilot data in 37 volunteers correlating with cuff-based blood pressure, and a targeted FDA 510(k) submission in Q1 2028.

What sets it apart

Electrical impedance sensing (Vascular Impedance Mapping) rather than optical PPG, aimed at more robust cardiovascular signal acquisition from the finger, paired with an in-house 18-30 month development model that carries a technology from validated IP through regulatory strategy to exit.

Funding history

1 round
Equity+2Jun 22, 2026
Form D
+$100K$100K total

Latest SEC filings

via EDGAR · CIK 0002082940
Form D · Jun 22, 2026NewView on EDGAR

Products

1 tracked

Safyr

Wearable medical device

A wearable cardiovascular sensing platform, in development, with a smart ring as the initial product form factor. It captures cardiovascular-related physiological signals from the periphery using a circular array of electrodes.

  • Vascular Impedance Mapping (VIM) electrical sensing rather than optical PPG
  • Circular multi-sensor electrode architecture around the finger
  • Smart ring form factor as the initial product pathway
  • US patent for VIM allowed by the USPTO in February 2026